DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Park BH, Hwang T, Liu TC. , et al.
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Lancet Oncol 2008;
9 (06) 533-542
We do not assume any responsibility for the contents of the web pages of other providers.